DNA Vaccine Epitope Insertion for Arteriosclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lipoprotein(a)-related diseases, such as arteriosclerosis, face challenges in effectively reducing plasma lipoprotein(a) levels and inducing neutralizing antibodies without triggering autoimmune reactions.
Innovation Solution
A DNA vaccine using a chimeric Hepatitis B virus core antigen polypeptide with a specific epitope of apolipoprotein(a) inserted between amino acid residues 80 and 81, administered to induce humoral immunity while minimizing self-reactive T-cell induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a DNA vaccine encoding apolipoprotein(a) is administered to induce neutralizing antibodies, then the effectiveness against lipoprotein(a)-related diseases is improved, but the risk of triggering autoimmune reactions increases
Solution Approach 1:
The apolipoprotein(a) is divided into specific epitope regions (Kringle IV type 2 repeats) that are targeted by the vaccine. By focusing on specific segments rather than the entire protein, the vaccine induces antibodies against particular pathogenic regions while avoiding recognition of other self-antigen regions, thereby reducing autoimmune reactions.
Solution Approach 2:
The vaccine design targets specific local regions (epitopes) of apolipoprotein(a) that are responsible for its pathogenic effects in lipoprotein(a). The Kringle IV type 2 repeat regions are identified as key epitopes for antibody induction, allowing localized immune response against the harmful portions of the protein.
2Adaptability or versatility
If the entire apolipoprotein(a) is used as antigen, then the immune response coverage is improved, but the specificity of neutralizing antibodies decreases
Solution Approach 1:
Instead of using the entire apolipoprotein(a) molecule, the vaccine focuses on specific segmented epitopes within the protein structure. The Kringle IV type 2 repeat regions are identified and targeted as discrete segments that provide both adequate immune coverage and high antibody specificity.
Solution Approach 2:
The vaccine uses specific epitope sequences from apolipoprotein(a) as intermediaries to trigger the immune response. These epitopic intermediaries (specific amino acid sequences in Kringle IV type 2 repeats) serve as the bridge between the antigen and the immune system, providing focused and specific antibody generation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine effectively suppresses lipoprotein(a) deposition and vascular intimal thickening, reducing inflammatory cytokines and preventing arteriosclerosis by inducing neutralizing antibodies without significant autoimmune side effects.
Implementation Method 1
Hepatitis B virus core (HBc) antigen protein constitutes spherical core particles by self assembly
Implementation Method 2
administering the aggravation factors, epitopes contained in the aggravation factors, or expression vectors encoding them to patients to induce the antibody to the aggravation factor in the body of patients
Implementation Method 3
unmethylated CpG motifs expressed with a plasmid unmethylated CpG motifs expressed with a plasmid backbone have been considered to be 'built-in' adjuvants, owing to their ability to activate the innate immune system by means of TLR9
Implementation Method 4
recent accumulating evidence suggests that the double-stranded structure of DNA, independently of CpG motifs, possesses immunomodulatory effects when introduced into the cytosol
Data Source
AI summary
The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.